Public Funding and Large Biopharma Investments Support Technological Advancements and Improved Analysis
In recent years, single-cell analysis has changed rapidly. It began as a niche, specialized technology with few companies offering solutions, which then became commonly used in academia. Subsequently, its use has spread to areas such as biopharma, with more companies investing in the research and development (R&D) of single-cell analysis projects.
Globally, the single-cell genomics and proteomics market is growing at high rates. The United States represents about 60% of the total market and is on track to increase about 12% to 16% annually. Much of that growth is characterized by public funding, such as funding by the National Institutes of Health (NIH) and increasing biopharma investments. Greater adoption and better handling of artificial intelligence (AI) and machine learning (ML) tools will drive this market’s growth. These novel tools encourage the development of software and data analysis solutions to help researchers interpret data.
This report examines the US single-cell genomics and proteomics market and provides a forecast from 2023 to 2028. It assesses the market for single-cell analysis tools used for analytical and isolation purposes across workflows, technologies, and applications. The research provides information on market concentration and evolution, leading providers, application areas, and technologies. This study will help vendors understand critical trends emerging for various application domains.
